David Gershenson

David Gershenson at MD Anderson has contributed to understanding and treating rare ovarian cancer histologies, particularly low-grade serous ovarian cancer (LGSOC) — a biologically distinct subtype with RAS/RAF pathway alterations rather than TP53 mutations, relative chemoresistance, but sensitivity to MEK inhibitors. His clinical research establishing clinical and molecular characteristics of LGSOC and MEK inhibitor activity in this subtype has been important for this underserved patient population.